WO2010051683A1 - 一种治疗急性肠炎和痢疾的组合物 - Google Patents

一种治疗急性肠炎和痢疾的组合物 Download PDF

Info

Publication number
WO2010051683A1
WO2010051683A1 PCT/CN2009/001034 CN2009001034W WO2010051683A1 WO 2010051683 A1 WO2010051683 A1 WO 2010051683A1 CN 2009001034 W CN2009001034 W CN 2009001034W WO 2010051683 A1 WO2010051683 A1 WO 2010051683A1
Authority
WO
WIPO (PCT)
Prior art keywords
parts
composition
palmatine
daidzin
puerarin
Prior art date
Application number
PCT/CN2009/001034
Other languages
English (en)
French (fr)
Inventor
张贵君
罗立宇
崔向微
Original Assignee
北京宏泰康达医药科技有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 北京宏泰康达医药科技有限公司 filed Critical 北京宏泰康达医药科技有限公司
Publication of WO2010051683A1 publication Critical patent/WO2010051683A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Definitions

  • Composition for treating acute enteritis and dysentery is provided.
  • the present application relates to the field of traditional Chinese medicine, and in particular to a composition for treating acute enteritis and dysentery. Background technique
  • Acute enteritis also known as acute gastroenteritis
  • Dysentery the ancient name of the intestines, stagnation. It is one of the acute intestinal infectious diseases. Chinese medicine believes that the disease is caused by the heat of the outside, the gas of the epidemic, the coldness of the internal injury, the damage to the spleen and stomach and the viscera, which belongs to the category of "intestinal diarrhea and dysentery”.
  • the dysentery is also ill, so there is no disease, no sputum, and sputum is wet, hot, and food.”
  • the treatment we should adopt the method of syndrome differentiation and treatment, "Jing Yue Quanshu""Cloud:”Where is the cure for dysentery, the most discerning In fact, the difference between cold and heat, the biggest relationship between this diarrhea, if the four are unknown, it is easy to kill. ", therefore, the disease is the first to distinguish cold, heat, deficiency, and reality.
  • abdominal pain, urgency, sputum, and sputum the clinical symptoms are fever, abdominal pain, urgency, and stool pus. Infected with epidemic disease, rapid onset, accompanied by sudden high fever, dizzy, horrified, for the epidemic.
  • the technical problem to be solved by the present application is to provide a composition preparation which is effective for treating acute enteritis and dysentery.
  • the present application discloses a composition for treating acute enteritis and dysentery, which is prepared by the following parts by weight ratio: puerarin 20-70 parts, daidzin 1-20 parts, baicalin 1-20 Serving, berberine 1-30 parts, palmatine 1-10 parts, ketone base 1-10 parts, glycyrrhizic acid 1-15 parts, glycyrrhizin 1-15 parts.
  • the composition for treating acute enteritis and dysentery may also be: puerarin 30-60 parts, daidzin 5-15 parts, baicalin 5-15 parts, berberine 2-8 parts , 3-8 parts of palmatine, 2-9 parts of jatrorrhizine, 3-13 parts of glycyrrhizic acid, 4-13 parts of glycyrrhizin.
  • the composition for treating acute enteritis and dysentery may also be: puerarin 40-50 parts, daidzin 8-13 parts, baicalin 7-12 parts, berberine 3-7 parts 4-7 parts of palmatine, 3-6 parts of jatrorrhizine, 5-11 parts of glycyrrhizic acid, 6-12 parts of glycyrrhizin.
  • the composition for treating acute enteritis and dysentery is: puerarin 45 parts, daidzin 11 parts, baicalin 9 parts, berberine 5 parts, palmatine 6 parts, medicine root 4 parts of base, 8 parts of glycyrrhizic acid, 9 parts of glycyrrhizin.
  • the composition for treating acute enteritis and dysentery described above characterized in that the composition is formulated into a tablet, an oral solution, a granule, a hard capsule, a soft capsule, a pill or a pill.
  • composition described above for use in the treatment of acute enteritis and dysentery.
  • composition of the present application has a definite curative effect, and the external dissolving muscles are evil to dissipate heat.
  • the heat of the inner clearing Yangming, the spleen and stomach spleen and stomach stagnation and stagnation of Shengjin, and the thick intestines stop phlegm.
  • a composition for treating acute enteritis and dysentery with a specific curative effect is 45 parts of puerarin, 11 parts of daidzin, 9 parts of baicalin, 5 parts of berberine, 6 parts of palmatine, medicine 4 parts of root base, 8 parts of glycyrrhizic acid, 9 parts of glycyrrhizin.
  • Case 1 Ms. Feng, 27 years old, complained of symptoms: nausea and vomiting, followed by diarrhea, watery stool, malodor, abdominal cramps, body aches, diagnosis of acute enteritis.
  • composition of the present application may also be in the following parts by weight ratio: 70 parts of puerarin, 20 parts of daidzin, 20 parts of baicalin, 30 parts of berberine, 10 parts of palmatine, 10 parts of jatrorrhizine, glycyrrhizic acid 15 Serve, 15 parts of glycyrrhizin.
  • Case 2 Mr. Yang, 20 years old, complained of symptoms: fever, body temperature up to 39 ° C, accompanied by nausea and vomiting, abdominal pain, diarrhea, stool more than 10 times a day, initially loose stool, followed by pus and blood, lower left abdomen tenderness With the bowel sounds hyperthyroidism, the urgency is heavy. The clinical diagnosis is dysentery.
  • composition of the present application may also be in the following parts by weight ratio: 20 parts of puerarin, 1 part of daidzin, 1 part of baicalin, 1 part of berberine, 1 part of palmatine, 1 part of jatrorrhizine, glycyrrhizic acid 1 Serve, 1 part of glycyrrhizin.
  • the oral liquid prepared by this application was effective after 2 days, the abdominal pain was relieved, the vomiting was stopped, and after 6 days, the blood in the stool disappeared, the number of bowel movements was reduced to 3 to 4 times, the symptoms were reduced, and the symptoms disappeared completely after 6 days.
  • composition of the present application may also be in the following parts by weight ratio: 50 parts of puerarin, 15 parts of daidzin, 10 parts of baicalin, 10 parts of berberine, 6 parts of palmatine, 5 parts of jatrorrhizine, glycyrrhizic acid 7 Serve, 6 parts of glycyrrhizin.
  • Treatment Using the hard capsules made in this application, taking 2 days, the symptoms are alleviated, the number of bowel movements is reduced to 2 times, and after 7 days, the symptoms disappear.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Description

一种治疗急性肠炎和痢疾的组合物 相关申请
本申请要求 2008 年 11 月 07 日提交的中国发明专利申请号 200810225958.5, 名称为 "一种治疗急性肠炎和痢疾的组合物" 的优先权， 其 作为整体在此引入作为参考。 技术领域
本申请涉及中药领域， 尤其涉及一种治疗急性肠炎和痢疾的组合物。 背景技术
急性肠炎又称急性胃肠炎， 是夏秋季的常见病、 多发病。 是由于 食进含有病原菌及其毒素的食物， 或饮食不当， 如过量的有刺激性的 不易消化的食物而引起的胃肠道粘膜的急性炎症性改变。 主要表现 为恶心、 呕吐、 腹痛、 腹泻； 发热等， 严重者可致脱水、 电解质紊 乱、 休克等。 病人多表现为恶心、 呕吐在先； 继以腹泻， 每日 3— 5次 甚至数十次不等， 大便多呈水样， 深黄色或带绿色， 恶臭， 可伴有腹 部绞痛、 发热、 全身酸痛等症状。
痢疾， 古称肠辟、 滞下。 为急性肠道传染病之一。 中医认为， 本 病多因外受湿热、 疫毒之气， 内伤饮食生冷， 损伤脾胃及脏腑而成， 属于"肠辟、 痢疾"范畴。 《素问 ·太阴阳明论》 云:"饮食不节， 起居不 时 ......下为飨泄， 久为肠辟。 "， 《证治汇补》 指出: "肠辟者， 谓湿热 积于肠中.即今痢疾也， 故曰无疾不成痢， 痢乃湿、 热、 食积三者"。 在 治疗上应采取辨证论治的方法， 《景岳全书》 '云: "凡治痢疾， 最当察虚 实， 辨寒热， 此泻痢最大关系， 若四者不明， 则杀人甚易也。 "， 故本 病辨证首辨寒、 热、 虚、 实， 临证当据腹痛、 里急后重、 痢色， 并参 合舌脉而辨， 临床以发热、 腹痛、 里急后重、 大便脓血为主要症状。 若感染疫毒， 发病急剧， 伴突然高热， 神昏、 惊厥者， 为疫毒痢。 痢 疾初起， 先见腹痛， 继而下痢， 日夜数次至数十次不等。 多发于夏秋 季节， 由湿热之邪， 内伤脾胃， 致脾失健运， 胃失消导， 更挟积滞， 酝酿肠道而成。 发明的公开
本申请所要解决的技术问题在于， 提供一种治疗急性肠炎和痢 疾， 疗效确切的组合物制剂。
为解决上述技术问题， 本申请公开了一种治疗急性肠炎和痢疾的 组合物， 由下列成分重量份数比制成： 葛根素 20-70份， 黄豆苷 1-20 份， 黄芩苷 1-20份， 小檗碱 1-30份， 巴马汀 1-10份， 药根碱 1-10 份， 甘草酸 1-15份， 甘草苷 1-15份。
所述治疗急性肠炎和痢疾的组合物， 各成分的重量份数比还可以 为： 葛根素 30-60份， 黄豆苷 5-15份， 黄芩苷 5-15份， 小檗碱 2-8 份， 巴马汀 3-8份， 药根碱 2-9份， 甘草酸 3-13份， 甘草苷 4-13份。
所述治疗急性肠炎和痢疾的组合物， 各成分的重量份数比还可以 为： 葛根素 40-50份， 黄豆苷 8-13份， 黄芩苷 7-12份， 小檗碱 3-7 份， 巴马汀 4-7份， 药根碱 3-6份， 甘草酸 5-11份， 甘草苷 6-12份。
所述治疗急性肠炎和痢疾的组合物， 各成分的重量份数比为： 葛 根素 45份， 黄豆苷 11份， 黄苓苷 9份， 小檗碱 5份， 巴马汀 6份， 药 根碱 4份， 甘草酸 8份， 甘草苷 9份。 以上所述治疗急性肠炎和痢疾的组合物， 其特征在于， 所述组合 物制成片剂、 口服液、 颗粒剂、 硬胶囊剂、 软胶囊剂、 滴丸剂或丸 剂。
以上所述的组合物， 用于治疗急性肠炎和痢疾的药物用途。
本申请的组合物疗效确切， 外解肌表之邪以散热.， 内清阳明之 热， 升发脾胃清阳之气止泻生津， 厚肠止痢。 实施发明的方式
以下列举实施例进一步对本申请加以详细说明：
实施例 1 :
一种治疗急性肠炎和痢疾， 疗效确切的组合物， 各成分的重量份 数比为葛根素 45份， 黄豆苷 11份， 黄芩苷 9份， 小檗碱 5份， 巴马汀 6份， 药根碱 4份， 甘草酸 8份， 甘草苷 9份。
病例 1 : 冯女士， 27岁， 主诉症状为： 恶心呕吐， 继以腹泻多 次， 大便多呈水样， 恶臭， 伴有腹部绞痛， 全身酸痛， 诊断为急性肠 炎。
治疗： 使用本申请制成的颗粒剂， 2天后见效， 腹泻症状减轻， 继 续服用 4天， 症状完全消失。
实施例 2:
本申请组合物配方还可以按以下重量份数比： 葛根素 70份， 黄豆 苷 20份， 黄芩苷 20份， 小檗碱 30份， 巴马汀 10份， 药根碱 10份， 甘草酸 15份， 甘草苷 15份。 病例 2： 杨先生， 20岁， 主诉症状为:发烧， 体温达 39°C， 伴有 恶心呕吐， 腹痛腹泻症状， 大便每日 10次以上， 初为稀便， 继呈脓血 便， 左下腹压痛伴肠鸣音亢进， 里急后重明显。 临床诊断为痢疾。
治疗： 使用本申请制成的滴丸剂， 3天后见效， 腹泻症状减轻， 便 血基本消失， 继续服用 6天后， 症状完全消失。
实施例 3 :
本申请组合物配方还可以按以下重量份数比： 葛根素 20份， 黄豆 苷 1份， 黄芩苷 1份， 小檗碱 1份， 巴马汀 1份， 药根碱 1份， 甘草酸 1份， 甘草苷 1份。
病例 3 赵先生， 42岁， 主诉症状为:发烧， 体温高达 40°C， 呕 吐， 腹痛， 里急后重明显， 排脓血便， 每日达数 10次， 并出现脱水症 状， 临床诊断为重型痢疾。
治疗： 使用本申请制成的口服液， 2天后见效， 腹痛减轻， 停止呕 吐， 继续服用 6天后， 便血消失， 排便次数减少至 3〜4次， 症状减 轻， 继续服用 6天后症状完全消失。
实施例 4:
本申请组合物配方还可以按以下重量份数比： 葛根素 50份， 黄豆 苷 15份， 黄芩苷 10份， 小檗碱 10份， 巴马汀 6份， 药根碱 5份， 甘 草酸 7份， 甘草苷 6份。
病例 4 李女士， 34岁， 主诉症状为:呕吐， 腹痛， 里急后重明 显， 大便多呈水样， 深黄色， 每日达数 4次， 临床诊断为急性肠炎。
治疗： 使用本申请制成的硬胶囊， 服用 2天， 症状减轻， 排便次 数减少至 2次， 服用 7天后， 症状消失。

Claims

权利要求
1. 一种治疗急性肠炎和痢疾的组合物， 其特征在于， 由下列成分 重量份数比制成： 葛根素 20-70份， 黄豆苷 1-20份， 黄芩苷 1-20份， 小檗碱 1-30份， 巴马汀 1-10份， 药根碱 1-10份， 甘草酸 1-15份， 甘 草苷 1-15份。
2. 根据权利要求 1所述的组合物， 其特征在于， 由下列成分重量 份数比制成： 葛根素 30-60份， 黄豆苷 5-15份， 黄芩苷 5-15份， 小檗 碱 2-8份， 巴马汀 3-8份， 药根碱 2-9份， 甘草酸 3-13份， 甘草苷 4-13 份。
3. 根据权利要求 1所述的组合物， 其特征在于， 由下列成分重量 份数比制成： 葛根素 40-50份， 黄豆苷 8-13份， 黄芩苷 7-12份， 小檗 碱 3-7份， 巴马汀 4-7份， 药根碱 3-6份， 甘草酸 5-11份， 甘草苷 6-12 份。
4. 根据权利要求 1所述的组合物， 其特征在于， 由下列成分重量 份数比制成： 葛根素 45份， 黄豆苷 11份， 黄芩苷 9份， 小檗碱 5份， 巴马汀 6份， 药根碱 4份， 甘草酸 8份， 甘草苷 9份。
5. 根据权利要求 1-4中任一项所述的组合物， 其特征在于， 所述 组合物制成片剂、 口服液、 颗粒剂、 硬胶囊剂、 软胶囊剂、 滴丸剂或 丸剂。
6. 权利要求 1-4中任一项所述的组合物在制备治疗急性肠炎和痢 疾的药物中的应用。
PCT/CN2009/001034 2008-11-07 2009-09-15 一种治疗急性肠炎和痢疾的组合物 WO2010051683A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN200810225958.5 2008-11-07
CN2008102259585A CN101411717B (zh) 2008-11-07 2008-11-07 一种治疗急性肠炎和痢疾的组合物

Publications (1)

Publication Number Publication Date
WO2010051683A1 true WO2010051683A1 (zh) 2010-05-14

Family

ID=40592596

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2009/001034 WO2010051683A1 (zh) 2008-11-07 2009-09-15 一种治疗急性肠炎和痢疾的组合物

Country Status (2)

Country Link
CN (1) CN101411717B (zh)
WO (1) WO2010051683A1 (zh)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102579439A (zh) * 2012-03-23 2012-07-18 重庆康刻尔制药有限公司 一种黄藤素组合药物、胶囊剂、制备方法及其应用
EP3600305A4 (en) * 2017-03-28 2021-06-16 IRP Health Pty Ltd BERBERIN ALKALOID FORMULATIONS FOR THE PREVENTION AND / OR TREATMENT OF INFECTIOUS DISEASES
CN117298131A (zh) * 2023-11-29 2023-12-29 唐宁医药科技(济南)有限公司 一种用于糖尿病足的甘草酸-药根碱纳米药物、制备方法及其应用

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105079223A (zh) * 2015-08-10 2015-11-25 陈彬 一种治疗寒湿阻滞型急性肠炎的中药组合物及其制备方法
CN106619682A (zh) * 2016-12-23 2017-05-10 郑州仁宏医药科技有限公司 一种治疗猪腹泻的药物组合物
CN106963777B (zh) * 2017-04-14 2020-07-14 宁夏医科大学 一种“黄芩苷-小檗碱”复合物的制备方法及其应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1517095A (zh) * 2003-01-14 2004-08-04 吉林天药科技股份有限公司 一种抗感染药物
CN101156906A (zh) * 2007-10-12 2008-04-09 南方医科大学 一种葛根芩连药物组合物

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1517095A (zh) * 2003-01-14 2004-08-04 吉林天药科技股份有限公司 一种抗感染药物
CN101156906A (zh) * 2007-10-12 2008-04-09 南方医科大学 一种葛根芩连药物组合物

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102579439A (zh) * 2012-03-23 2012-07-18 重庆康刻尔制药有限公司 一种黄藤素组合药物、胶囊剂、制备方法及其应用
EP3600305A4 (en) * 2017-03-28 2021-06-16 IRP Health Pty Ltd BERBERIN ALKALOID FORMULATIONS FOR THE PREVENTION AND / OR TREATMENT OF INFECTIOUS DISEASES
CN117298131A (zh) * 2023-11-29 2023-12-29 唐宁医药科技(济南)有限公司 一种用于糖尿病足的甘草酸-药根碱纳米药物、制备方法及其应用
CN117298131B (zh) * 2023-11-29 2024-02-23 唐宁医药科技(济南)有限公司 一种用于糖尿病足的甘草酸-药根碱纳米药物、制备方法及其应用

Also Published As

Publication number Publication date
CN101411717A (zh) 2009-04-22
CN101411717B (zh) 2010-10-13

Similar Documents

Publication Publication Date Title
WO2010051683A1 (zh) 一种治疗急性肠炎和痢疾的组合物
WO2013102410A1 (zh) 一种治疗过敏性咳嗽的口服液
CN101306180B (zh) 一种治疗胃病的药物
WO2006081743A1 (fr) Medicament destine au traitement de l'erosion cervicale et procede de preparation de celui-ci
CN115708843B (zh) 益气活血解毒方及其应用
CN107468680B (zh) 二氢丹参酮ⅰ在制备治疗溃疡性结肠炎药物中的应用
CN104352989A (zh) 一种治疗黄疸的药物组合物
CN103463400B (zh) 治疗小儿哮喘的中药组合物
CN103463399B (zh) 治疗小儿哮喘的药物及其制备方法
CN103585580B (zh) 一种用于复发性口腔溃疡的中药制剂
CN103689487B (zh) 一种石榴皮山药分散片及制备方法
CN102274428B (zh) 一种具有治疗肠易激综合症作用的药物组合物及其制备方法和应用
CN106214862A (zh) 一种防治鸡非典型性新城疫的中兽药口服液及其制备方法
CN103463401B (zh) 小儿用哮喘药
CN101693077B (zh) 一种用于治疗热性支气管哮喘和慢性支气管炎的药物
CN103463402B (zh) 小儿哮喘用中药组合物及其制备方法
CN105477148A (zh) 一种治疗小儿湿疹的外洗壮药组合物
CN105193980A (zh) 一种防治水产动物出血病的中药组合物
CN103463403B (zh) 小儿哮喘用药物组合物
CN102657692A (zh) 一种用于治疗鸡沙门氏菌病的中药颗粒剂及其制备方法
CN116531471B (zh) 一种用于治疗病毒感染湿热袭肺证的中药合剂
CN1931311A (zh) 一种治疗银屑病的中药制剂
CN108030886A (zh) 一种用于治疗小儿肺炎支原体肺炎的中药糖浆剂
CN105031600A (zh) 一种治疗小儿急性腹泻的栓剂及制备方法
CN104940768B (zh) 一种治疗慢性支气管炎的中药组合物及其制备方法

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09824340

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 09824340

Country of ref document: EP

Kind code of ref document: A1